BMY - Bristol-Myers Squibb

-

$undefined

N/A

(N/A)

Bristol-Myers Squibb NEW YORK STOCK EXCHANGE INC.:BMY Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Location: 430 E 29th St Fl 14, New York, 10016-8367, US | Website: www.bms.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

156.5B

Cash

8.094B

Avg Qtr Burn

N/A

Short % of Float

1.23%

Insider Ownership

0.12%

Institutional Own.

78.54%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
KRAZATI (Adagrasib) + Cetuximab Details
Cancer, Colorectal cancer , Solid tumor/s

Approved

Quarterly sales

Opdivo® (nivolumab) + chemotherapy Details
Cancer, Non-small cell lung carcinoma

Approved

Quarterly sales

Reblozyl®(luspatercept-aamt) Details
Cancer, Anemia, Blood cancer, Mutant Myelodysplastic Syndromes

Approved

Quarterly sales

Camzyos®(mavacamten) Details
Hypertrophic cardiomyopathies

Approved

Quarterly sales

Zeposia (ozanimod) Details
Multiple sclerosis, Ulcerative colitis

Approved

Quarterly sales

Breyanzi® (lisocabtagene maraleucel) Details
Chronic lymphocytic leukemia, Blood cancer, Small lymphocytic lymphoma

Approved

Quarterly sales

Augtyro™ (Repotrectinib) Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Approved

Quarterly sales

Approved

Quarterly sales

KRAZATI (Adagrasib) Details
Cancer, Lung cancer, Non-small cell lung carcinoma, Solid tumor/s, Colorectal cancer

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Eliquis Details
Stroke, Atrial fibrillation, Blood clots

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Sotyktu (deucravacitinib) Details
Psoriasis, Skin disease/disorder

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

OPDIVO (nivolumab) injection Details
Gastric cancer, Gastroesophageal adenocarcinomas

PDUFA

Approval decision

PDUFA

Approval decision

BMS-986278 [(LPA1) antagonist] Details
Lung disease, Idiopathic pulmonary fibrosis

Phase 3

Data readout

Milvexian Details
Acute coronary syndrome, Stroke, Atrial fibrillation

Phase 3

Data readout

KarXT (M1/M4 muscarinic agonist) Details
Schizophrenia, Mental health, Alzheimer's disease

Phase 3

Data readout

KarXT (M1/M4 muscarinic agonist) Details
Mental health, Schizophrenia

Phase 3

Data readout

Adagrasib (KRAZATI®) + Pembrolizumab Details
Lung cancer, Cancer, Non-small cell lung carcinoma, Solid tumor/s

Phase 3

Update

Phase 3

Update

KRAZATI (Adagrasib) Details
Non-small cell lung carcinoma, Cancer, Lung cancer, Solid tumor/s

Phase 3

Update

Phase 3

Update

Opdivo® (nivolumab) + Yervoy (ipilimumab) Details
Non-small cell lung carcinoma, Cancer

Phase 3

Update

Phase 3

Update

Phase 3

Update

Adagrasib (KRAZATI®) + Cetuximab Details
Solid tumor/s, Colorectal cancer , Cancer

Phase 3

Update

Phase 3

Update

Phase 3

Update

A/I CELMoD (CC-99282) Details
Relapsed/ refractory lymphoma, Non-Hodgkin lymphoma, Cancer

Phase 2

Interim update

Phase 2

Initiation

Phase 1/2

Data readout

Phase 1/2

Data readout

Golcadomide (CELMoD™ Agent) +rituximab Details
Blood cancer, Diffuse large B cell lymphoma, Non-Hodgkin lymphoma

Phase 1/2

Update

MRTX1133 Details
Cancer, Solid tumor/s, Colorectal cancer , Pancreatic cancer, Lung cancer

Phase 1/2

Update

Adagrasib (KRAZATI®) + VS-6766 Details
Lung cancer, Cancer, Non-small cell lung carcinoma, Solid tumor/s

Phase 1/2

Initiation

Golcadomide (CELMoD™ Agent) Details
Blood cancer, Non-Hodgkin lymphoma

Phase 1b

Update

KarXT (M1/M4 muscarinic agonist) Details
Schizophrenia, Mental health

Phase 1b

Update

KAR-2618 Details
Mental health, Major depressive disorder

Phase 1b

Initiation

BMS-986393/CC-95266 Details
High Refractory Multiple Myeloma

Phase 1

Update

BMS-986365 (CC-94676) Details
Castration-resistant prostate cancer

Phase 1

Update